VIM and breast cancer: STAT3 signaling pathway plays a crucial role in proliferation (Bcl-2, Survivin), angiogenesis (HIF1α, VEGF), and epithelial-mesenchymal transition (Vimentin, MMP-9) in breast cancer cells and has been validated as a drug target for cancer therapy [41,42,43].